NRx Pharmaceuticals raises $1.2M via private placement of preferred shares and warrants at $0.40

NRX Pharmaceuticals, Inc.

Issued 3M shares of Series A Preferred Stock and 3M warrants, each at $0.40, raising ~$1.2M from existing investors.
Preferred shares convert to common stock after 6 months or earlier if stock price reaches $1.20 per share.
Warrants exercisable at $0.40 per share for 5 years, also early conversion if $1.20 trigger met.
Proceeds to fund development of NRX-101 for Suicidal Bipolar Depression and Chronic Pain, plus general corporate purposes.
Certificate of Designation filed with Delaware authorizing up to 12M shares of Series A Preferred.

item 1.01 item 3.02 item 5.03 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

NRX Pharmaceuticals, Inc.: Filed Certificate of Designation for Series A Convertible Preferred Stock, establishing preferences, rights, and limitations (effective 2023-08-30).

Change: charter amendment
Effective: 2023-08-30

Exact text from the filing

On August 30, 2023, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock with the Delaware Secretary of State (the "Certificate of Designation") authorizing up to 12,000,000 shares of Series A Convertible Preferred Stock.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

NRX Pharmaceuticals, Inc. entered into Securities Purchase Agreement with the purchasers signatory thereto (the "Investors") valued at approximately $1.2 million (effective 2023-08-28).

Action: entry
Agreement: equity purchase
Counterparty: the purchasers signatory thereto (the "Investors")
Value: approximately $1.2 million
Effective: 2023-08-28

Exact text from the filing

On August 28, 2023, the Company entered into a securities purchase agreement (the "Securities Purchase Agreement") with the purchasers signatory thereto (the "Investors"), pursuant to which the Company issued 3,000,000 shares of the Company’s Series A Convertible Preferred Stock, par value $0.001 per share (the " Series A Preferred Stock "), and one (1) investor warrant (each an "Investor Warrant") for every share of Series A Convertible Preferred Stock issued.

View on SEC.gov

Browse all governance changes →

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-097804

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.